KRAS and intrahepatic cholangiocarcinoma: We defined 20 FMGs in ICC samples from the ICGC cohort, which were TP53 (35%), ARID1A (19%), KRAS (18%), SMAD4 (14%), SYNE1 (11%), MUC16 (11%), BAP1 (9%), LRP1B (9%), FSIP2 (9%), and EPHA2 (9%) (Figure 1A).